Introduction
In recent years several antibody-based therapies that target tumour-associated membrane antigens have entered clinical trials with promising results [1] [2] [3] . However, curative treatment is frequently not achieved due to therapy-resistant recurrences emerging after initial rounds of seemingly successful treatment [4] [5] [6] . It has been shown that within one tumour mass different stages of malignant progression and various oncogenic mutations can occur simultaneously, leading to the development of heterogeneous tumour cell phenotypes [7] [8] [9] [10] [11] [12] .
Heterogeneous and lost target antigen expression are likely to be responsible for many of the therapeutic failures observed in current antibody-based therapies [4] [5] [6] . Therefore, strategies have been developed to take advantage of the so-called 'bystander effect', which aims to eliminate tumour cells with reduced or lost target antigen expression. The bystander effect is based on the principle that targeted tumour cells are not only eliminated, but are also exploited to convey the therapeutic effect towards neighbouring tumour cells devoid of target antigen expression. Bystander effects have been described for several antibody-based therapeutic approaches 13, 14 , and more recently
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for gene therapy using FASL and TRAIL, two members of the Tumour Necrosis Family of death inducing ligands [15] [16] [17] [18] . TRAIL is of particular interest for its tumour-restricted apoptosis inducing capacity in a wide range of neoplastic cells while sparing normal tissues. TRAIL is expressed as a type II transmembrane protein (memTRAIL) 19,20 on a broad spectrum of tissues ranging from peripheral blood lymphocytes, spleen, and thymocytes to many solid organs but is absent in brain, liver, and testis.
A unique TRAIL receptor system has been uncovered in which the distinct receptors TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, and osteoprotegerin (OPG), can differentially bind and interact with TRAIL. After ligation, TRAIL-R1 and TRAIL-R2 recruit the intracellular FAS-associated Death Domain adapter protein (FADD) and the initiator caspase-8 or -10, thereby forming the Death Inducing Signalling Complex (DISC) [21] [22] [23] [24] [25] [26] [27] [28] . Assembly of the DISC results in activation of caspase-8 or -10 that subsequently cleave and activate effector caspases, such as caspase-3, -6, and -7, leading to e.g. PARP cleavage and ultimately apoptotic cell death. TRAIL-R3, TRAIL-R4, and OPG lack (functional) death domains and after ligation, do not induce apoptosis.
TRAIL-R1 and TRAIL-R2 have a broad and partly overlapping pattern of expression, suggesting that they may serve as an alternate or 'backup' system, allowing the immune system to control aberrant cells even if one of the receptors has failed. Recently, it was
shown that TRAIL-R1 and TRAIL-R2 have rather distinct crosslinking requirements for the initiation of apoptosis 29 . Both recombinant soluble TRAIL (sTRAIL), consisting of the extra-cellular domain of TRAIL, and memTRAIL can efficiently activate TRAIL-R1 even at low concentrations, whereas TRAIL-R2 can only be activated by memTRAIL or sTRAIL that is secondarily crosslinked by antibodies.
To date, various forms of recombinant soluble TRAIL have been generated of which potent In the present study, we analyzed whether targeting of scFvC54:sTRAIL to EGP2-positive cells can be used to convey a pro-apoptotic bystander effect towards neighbouring tumour cells devoid of EGP2 expression, as schematically depicted in Fig.1 . Interestingly, we observed an exceptionally potent bystander apoptotic effect of scFvC54:sTRAIL, which critically depended on the presence of EGP2-positive target cells. Bystander apoptosis induction by scFvC54:sTRAIL might be applicable for the treatment of human cancer cells that escape current antibody-based therapy due to partial loss of target antigen expression. 
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Cell lines and EGP2 transfectants
Human cell lines Jurkat (acute lymphoblastic T cell leukemia), Ramos (B cell lymphoma), and U87MG (glioblastoma), all of which are EGP2-negative, were purchased from the ATCC.
EGP2-positive variants of the above cell lines were generated by retroviral transduction.
In short, EGP2 cDNA was cloned into a retroviral vector derivative of LZRS-pBMN-lacZ Almere, The Netherlands). Transfected cells were selected by culturing in the presence of 1 µg/ml puromycin, 300 µg/ml hygromycin, and 1 µg/ml diphtheria toxin (BD Biosciences Clontech, Palo Alto, USA). Viral particle-containing supernatant was harvested after 3 days and used to transduce Jurkat, Ramos and U87MG cells. After overnight incubation, viral particle-containing supernatant was replaced by fresh medium. 
Expression of TRAIL receptors
Membrane expression levels of TRAIL-receptors 1, 2, 3, and 4, were analyzed by flow cytometry using a TRAIL-receptor antibody kit purchased from Alexis. Briefly, cells were harvested, washed using serum free RPMI, and resuspended in 100 µl fresh medium containing the appropriate primary MAb. Specific binding of the primary antibody was detected using a PE-conjugated secondary antibody (DAKO, Glostrup, Denmark). All antibody incubations were performed at 0°C for 45 min and were followed by two washes with serum free medium.
Production of scFvC54:sTRAIL
The fusion protein scFvC54:sTRAIL, comprising the scFvC54 targeting domain, an intra-chain linker, and the sTRAIL effector domain, was produced in Chinese Hamster
Ovary (CHO-K1) cells as previously described
34
. Briefly, the expression plasmid pEE14scFvC54:sTRAIL was transfected to CHO-K1 cells, after which cells were selected for amplified medium secretion of the fusion protein using the glutamine synthetase method as described before
39
. Single cell sorting of transfectants using the MoFlo high speed cell sorter (Cytomation) identified CHO-K1 clone 70C1 that stably secreted 3.44 µg/ml scFvC54:sTRAIL into the culture medium. Using the same procedures, Mock-scFvH22:sTRAIL, directed at the antigen CD64, not present on the cell lines used in this study, was generated and added in experiments where indicated.
Apoptosis induction assessed by viability assay
Where indicated, apoptosis induction apparent from loss of tumour cell viability was assessed by MTS assay (Promega Benelux b.v., Leiden, The Netherlands). Briefly, cells were seeded in flat bottom 96-well micro culture plates at a density of 3•10 4 cells/well in 100 µl medium. After overnight culture, medium was replaced with fresh medium containing the various experimental conditions. After 16 h, MTS assay was performed according to manufacturer's recommendations. Experimental apoptosis induction was quantified as the percentage apoptosis compared to medium control, which was set at 0% apoptosis. Each experimental and control group consisted of six independent wells.
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Apoptosis induction assessed by loss of Mitochondrial Membrane Potential (∆Ψ)
Where indicated, apoptosis induction apparent from loss of ∆Ψ was analyzed using the cell-permeant green-fluorescent lipophilic dye DiOC6 (Molecular Probes, Eugene, USA) as previously described 40 . In short, after 16 h treatment cells were harvested by centrifugation (300xg; 5 min) and incubated for 30 min at 37°C with fresh medium containing 0.1 µM DiOC6, washed twice with phosphate buffered saline (PBS), and analyzed using flow cytometry.
Immunoblot analysis of caspase activation and PARP cleavage
Where indicated, apoptosis induction apparent from caspase-8 and caspase-3 activation and PARP degradation was assessed by immunoblot analysis using antibodies against active caspase-8 (Cell signalling technology, Beverly, MA, USA), active caspase-3 (BD biosciences, San Jose, CA, USA), and PARP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) respectively. Briefly, cells were seeded in 6 well plates at a final concentration of 0.5•10 6 cells/ml and treated as indicated. Cells were harvested by centrifugation (2,000xg; 10 min), lysed in lysis buffer (20 mM Tris-HCl, 5.0 mM EDTA, 2.0 mM EGTA, 100 mM NaCl, 0.05% SDS, 0.50% NP-40, 1 mM PMSF, 10 µg/ml Aprotein, 10 µg/ml Leupeptin, pH 6.8), and sonicated on ice for 2x5 sec. Cleared supernatants were collected after centrifugation (15,000xg; 10min) and protein concentration was determined using Bradford method according to manufacturer's instructions (BioRad, Hercules, CA, USA). Samples were diluted 1:1 in standard SDS/PAGE-loading buffer containing 2-mercapto-ethanol and boiled for 10 minutes. Samples of 30 µg total protein were loaded and separated using 10% acryl amide SDS-PAGE, followed by electroblot transfer to nitrocellulose. Blots were incubated with the respective primary MAbs and appropriate HRPO-conjugated secondary antibodies. Specific binding of MAbs was detected using ECL (Roche diagnostics, Indianapolis, IN, USA). All antibody incubations were performed at room temperature for 1.5 h in PBS containing 5% bovine serum albumin, followed by 3 washes with PBS containing 0.1% Tween-20.
Distinctive fluorescent labelling of target and bystander cells
Differential cell membrane labelling of target and bystander cells was achieved using the 
FACS-sorting of target and bystander cells after treatment
FACS-sorting was applied to separate mixed target cells and bystander cells after treatment with scFvC54:sTRAIL. To this end, DiI-labelled bystander cells (Jurkat) were mixed with an equal amount of unlabelled target cells (Jurkat.EGP2) at a final concentration of 0.5•10 6 cells/ml. This mixed cell culture was treated with scFvC54:sTRAIL (300 ng/ml) for 6 h in the presence or absence of MAbs MOC31 (5 µg/ml) or 2E5 (1 µg/ml). After treatment, cell mixtures were collected and washed twice in fresh medium pre-cooled at 0°C. Subsequently, 2.5•10 6 cells of both the target and bystander cells were sorted using the MoFlo high-speed cell sorter. The sorted cells were found to be >99% pure and were separately analyzed for apoptotic features by immunoblot as described above.
Fluorescence microscopy of bystander apoptosis induction
Fluorescent microscopy was used to visualize bystander apoptosis induction in the adherent growing glioblastoma cell line U87MG. U87MG.EGP2 target cells, brightly expressing EGFP, were mixed at a 1:4 ratio with U87MG bystander cells at a final concentration of 0.5•10 6 cells/well on Lab-Tek chamber slides (Nalge Nunc int., Naperville, IL, USA). After overnight culture, spent medium was carefully aspirated and the mixed cell culture was subjected to treatment with scFvC54:sTRAIL (300 ng/ml) for 16 h, in the presence or absence of MAb MOC31 (5 µg/ml) or MAb 2E5 (1 µg/ml), respectively. After treatment, apoptosis induction apparent from nuclear morphology was analyzed using the DNA binding dye Hoechst 33342 (Molecular probes). Both nuclear morphology and EGFPfluorescence were visualized using a Quantimed 600S fluorescence microscope (Leica Camera Ag, Solms, Germany).
Quantification of innocent bystander apoptosis in isolated PBMCs
Leukocytes were isolated from EDTA anti-coagulated blood of healthy donors using the Ammonium Chloride method according to standard procedure. Briefly, blood was diluted 
Results
TRAIL-R expression in EGP2-transduced cell lines
Flow cytometric analysis of the retrovirally transduced cell lines Jurkat.EGP2, Ramos.EGP2, and U87MG.EGP2 revealed a strong homogeneous cell surface expression of EGP2 and intracellular EGFP fluorescence (data not shown). No significant differences in TRAIL receptor expression patterns were found between parental and EGP2-transduced cell lines (Table 1) .
Target cell-restricted apoptosis induction by scFvC54:sTRAIL EGP2-negative bystander cells (Jurkat, Ramos, U87MG) were not susceptible to apoptosis induction by scFvC54:sTRAIL. After prolonged treatment (16 h) with 300 ng/ml scFvC54:sTRAIL, cell cultures contained only low percentages of apoptotic cells ( Fig.2A; 5%, 10%, and 3%, for Jurkat, Ramos, and U87MG, respectively). When treatment was performed in the presence of multimeric soluble EGP2 (3.5 µg/ml), which secondarily crosslinks scFvC54:sTRAIL, a strong increase in the percentages of apoptotic cells was observed (92%, 84%, and 70% for Jurkat, Ramos and U87MG, respectively).
Treatment of EGP2-positive target cells (Jurkat.EGP2, Ramos.EGP2, and U87MG.EGP2) with 300 ng/ml scFvC54:sTRAIL induced a strong increase in percentage of apoptotic cells ( Fig.2B ; 71%, 67%, 65%, respectively). Treatment of these EGP2-positive cells in the presence of EGP2-blocking MAb MOC31 strongly inhibited apoptosis induction (16%, 13%, and 5%, for Jurkat.EGP2, Ramos.EGP2 and U87MG.EGP2, respectively).
Interestingly, although levels of TRAIL receptor expression were comparable for both parental and EGP2-transduced cell lines, the sensitivity to apoptosis induction by scFvC54:sTRAIL was somewhat reduced in the EGP2-transduced cell lines. Reduced sensitivity of EGP2-transduced cells may be related to the retroviral transduction procedure of these cell lines or to the ectopic overexpression of EGP2.
Distinctive quantification of apoptosis induction in target and bystander cells
When mixed cultures of Jurkat.EGP2 target cells and Jurkat bystander cells were treated with scFvC54:sTRAIL, strong apoptosis induction was observed in Jurkat.EGP2 target cells ranging from 55% at target to bystander ratio 7:3 to 20% at ratio 1:100 (Fig.3A) .
Apoptosis induction in Jurkat bystander cells ranged from 80% at ratio 7:3 to 17% at the remarkably low ratio 1:100 (Fig.3B) . Treatment of bystander cells alone resulted in marginal induction of apoptosis (7%). Percentages of apoptotic cells were strongly reduced in both target and bystander cell populations when treatment was performed in the presence of EGP2-blocking MAb MOC31 (Fig.3A and B) . Analogously, treatment with scFvC54:sTRAIL in the presence of TRAIL neutralizing MAb 2E5 completely abrogated apoptosis ( Fig.3A and B) . Furthermore, when mixed cultures of target and bystander cells were treated with the Mock-scFvH22:sTRAIL fusion protein, containing the antibody fragment domain scFvH22 of irrelevant specificity, no apoptosis induction was found in Jurkat.EGP2 target or Jurkat bystander cells (Fig.3C ). Similar experiments with mixed cultures of Ramos.EGP2 and Ramos, and the adherent cell lines U87MG.EGP2 and U87MG, further confirmed that treatment with scFvC54:sTRAIL potently induced both target and bystander apoptosis, whereas treatment with Mock-scFvH22:sTRAIL did not lead to significant apoptosis induction in target or bystander cells (Fig.3C ).
Target and bystander apoptosis induction is caspase-8 dependent
In a mixed culture of Ramos.EGP2 target cells and Ramos bystander cells (ratio 2:3), treatment with scFvC54:sTRAIL resulted in bystander apoptosis induction up to 65% (Fig.4A) . Treatment in the presence of the specific caspase-8 inhibitor Z-IETD-FMK strongly inhibited apoptosis induction in both target and bystander cells ( 
Immunoblot analysis of FACS-sorted target and bystander cells
Post-treatment sorting of a mixed culture of Jurkat.EGP2 target and Jurkat bystander cells (ratio 1:1), allowed for the separate evaluation of apoptotic features in target and bystander cells. Treatment with scFvC54:sTRAIL induced a clear activation of caspase-8 and caspase-3 in both Jurkat.EGP2 target cells (Fig.5A , lane 2) and Jurkat bystander cells (Fig.5B, lane 2) . Activation of caspase-3 was accompanied by cleavage of its target protein PARP (Fig.5A and B, lane 2). Treatment in the presence of MAb MOC31 or MAb 2E5 inhibited caspase activation and PARP cleavage in both target and bystander cells ( Fig.5A and B, lane 3 and 4, respectively). Neither caspase activation nor PARP cleavage was observed when Jurkat bystander cells were treated in the absence of Jurkat.EGP2 target cells, even when treatment was prolonged to 24 h (data not shown).
Fluorescent microscopy of bystander apoptosis induction
Microscopic evaluation of untreated mixed cultures revealed that adherent U87MG.EGP2 target cells and U87MG bystander cells were interconnected by cellular protrusions (Fig.6A ). Protrusions coming from U87MG.EGP2 target cells can be appreciated due to the EGFP-fluorescence present in the cytoplasm of these cells. When Fig.6 . Visualization of bystander apoptosis by fluorescence microscopy. U87MG.EGP2 target cells and U87MG bystander cells were mixed at a target-to-bystander ratio of 1:4 and precultured on chamber slides. Subsequently, the mixed cultures were subjected for 16 hours to treatment with (A) medium, (B) scFvC54:sTRAIL (300 ng/ml), (C) MAb MOC31 (5 µg/ml) + scFvC54:sTRAIL, and (D) MAb 2E5 (1 µg/ml) + scFvC54:sTRAIL. After treatment, cells were stained using the nuclear stain Hoechst and analyzed for characteristic apoptotic morphology. Target and bystander cells could be distinctly discriminated due to the expression of green fluorescent protein by U87MG.EGP2 target cells only.
a mixed culture of U87MG.EGP2 target cells and U87MG bystander cells (ratio 1:4) was treated with 300 ng/ml scFvC54:sTRAIL for 16 h, pronounced apoptotic morphological features such as membrane blebbing and nuclear condensation were visible in both target and bystander cells. The efficacy of the bystander effect was apparent from the fact that apoptotic morphology was observed in almost all U87MG bystander cells (Fig.6B ).
Identical treatment in the presence of either MAb MOC31 or MAb 2E5 strongly inhibited the appearance of apoptotic morphology in both U87MG.EGP2 target cells and U87MG
bystander cells ( Fig.6C and D) .
No innocent bystander apoptosis in isolated PBMCs
Treatment of mixed cultures of isolated leukocytes (innocent bystander cells) and
Jurkat.EGP2 cells with scFvC54:sTRAIL did not lead to any significant induction of apoptosis in the bystander leukocytes (Fig.7) , whereas apoptosis of up to 46% was observed in Jurkat.EGP2 target cells. Apoptosis in Jurkat.EGP2 was specifically inhibited when treatment was performed in the presence of MAb MOC31 or MAb 2E5.
Discussion
It has been shown that crosslinking of TRAIL-receptors is crucial for the efficient induction of apoptosis in tumour cells. Previously, we reported on target cell-restricted fratricide apoptosis induction by the fusion protein scFvC54:sTRAIL, due to the efficient All EGP2-negative bystander cell types used were fully resistant to prolonged treatment with scFvC54:sTRAIL (16h, 300 ng/ml). However, when mixed cultures of EGP2-positive target cells and corresponding EGP2-negative bystander cells were treated, potent proapoptotic effects of up to 80% apoptosis induction were achieved in EGP2-negative bystander cells (Fig.3A) . Pro-apoptotic bystander activity of scFvC54:sTRAIL was observed for both suspension tumour cell types (Jurkat and Ramos) and for adherent U87MG glioblastoma cells (Fig.3C ).
Treatment of mixed cultures containing as little as 1% of EGP2-positive target cells still showed significant apoptosis induction of up to 17% in EGP2-negative bystander cells.
This clearly indicated that significant pro-apoptotic bystander activity of scFvC54:sTRAIL can be achieved at low target-to bystander cell ratios. Treatment in the presence of an EGP2-blocking antibody or a TRAIL-neutralizing antibody strongly inhibited apoptosis induction in both target and bystander cells at all ratios analyzed ( Fig.3A and B) . When treatment was performed using identical amounts of a scFv:sTRAIL fusion protein of irrelevant specificity (Mock-scFvH22:sTRAIL), no induction of apoptosis was observed (Fig.3C) . Furthermore, apoptosis induction was specifically absent in bystander cells that ectopically over-expressed c-FLIP L , a specific inhibitor of death receptor-induced apoptosis (Fig.4B ). Immunoblot analysis of post treatment-sorted target and bystander cells demonstrated identical activation profiles of caspase-3 and caspase-8, and cleavage of PARP ( Fig.5A and B) . Together these results all indicated that both fratricide and bystander apoptosis induction by scFvC54:sTRAIL is mediated by target cell-dependent inter-cellular crosslinking of agonistic TRAIL-receptors.
Microscopic evaluation of a mixed culture (ratio 1:4) of adherent U87MG.EGP2 target cells and U87MG bystander cells treated with scFvC54:sTRAIL visualized pronounced apoptotic morphological features (nuclear condensation and membrane blebbing) in both target and bystander cells. The strong bystander effect observed here might partly be due to the fact that U87MG cells have extensive cellular protrusions that appear to make multiple intracellular connections even to more distant cells (Fig.6A) . Possibly, this particular cell morphology influences TRAIL-receptor crosslinking by scFvC54:sTRAIL between interconnected target-and bystander cells. It is tentative to speculate that scFv:sTRAIL treatment of target cells with more extensive cellular protrusions may induce apoptosis in more distant bystander cells.
As discussed above, we analyzed the pro-apoptotic bystander effect by scFvC54:sTRAIL down to extremely low target to bystander cell ratios. We noticed that when treatment was performed at ratios < 1:10, apoptosis induction in the target cells was partly diminished (Fig.3A ). It appears that the presence of a vast majority of bystander cells reduces direct cellular contacts between EGP2-positive target cells, subsequently reducing fratricide apoptosis induction of these cells. The inhibitory effect of bystander cells on fratricide apoptosis induction in target cells was not observed at higher and possibly more realistic target-to-bystander cell ratios.
Previously, bystander effects have been observed in ADEPT (antibody-directed enzyme prodrug therapy) 41 and VDEPT (virus-directed enzyme prodrug therapy) 13, 42 , therapeutic approaches that target a non-human prodrug-converting enzyme into tumour cells and involve the transfer and diffusion of toxic metabolites from one cell to another.
Usually, the toxic metabolites produced using these strategies cannot freely transit the cell membrane. Consequently, these bystander effects chiefly depend on GJIC between target and bystander tumour cells 14, [43] [44] [45] . Unfortunately, most cancer cells lack functional GJIC. The bystander apoptosis activity described here for scFvC54:sTRAIL does not require internalization, enzymatic conversion, diffusion, or gap junctional intercellular communication (GJIC) between target and bystander cells.
An additional problem in both ADEPT and VDEPT appears to be the preferential killing of targeted cells due to their relative high intracellular concentration of the toxic metabolite, resulting in a decreased bystander effect. In contrast, the bystander activity of scFvC54:sTRAIL is likely to be maintained during the whole process of target cell apoptosis induction. Moreover, apoptosis of a given target cell can yield numerous minute apoptotic bodies with intact EGP2-positive cellular membranes. In vitro, target cellderived apoptotic bodies displaying scFvC54:sTRAIL might continue to contribute to the crosslinking of TRAIL receptors and potentially disseminate the bystander effect to more distant tumour cells. The presence and subsequent contribution of such apoptotic bodies to the bystander effect studied here remains to be clarified. However, in vivo it is likely that phagocytosing cells of the immune system rapidly scavenge such apoptotic bodies Potent anti-tumour bystander effect by scFvC54:sTRAIL Neoplasia 2004, Sept-Okt, Volume 6, Number 5: 300-310.
before additional bystander apoptosis induction is initiated.
We wondered whether the potent pro-apoptotic bystander effect of scFvC54:sTRAIL might also result in the killing of 'innocent bystander' cells such as normal blood cells.
Therefore, we added freshly isolated leukocytes to various bystander experiments and found no significant signs of apoptosis induction in the various blood cell types (Fig.7) . This indicates that at least in this experimental setting scFvC54:sTRAIL has retained its tumour selective apoptosis activity with no signs of innocent bystander apoptosis induction. Nevertheless, from the present study it cannot be excluded that scFvC54:sTRAIL might exert toxic or innocent bystander effects towards other normal cells and tissues. Toxicity studies of scFvC54:sTRAIL can possibly be performed in our human EGP2 transgenic mouse model 46 in which human EGP2 expression displays authentic expression patterns in mouse epithelia.
In conclusion, this is the first example of target cell-dependent bystander apoptotic activity by a scFv:sTRAIL fusion protein. Further development of this new principle is warranted for TRAIL and antibody-based therapy of human cancers that escape current antibody-based therapy due to heterogeneous target antigen expression.
